B+
Bull case
25%
Probability
Target price
$17.00
+5.6% vs current
IART
Integra LifeSciencesBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$14.50
-9.9% vs current
B-
Bear case
25%
Probability
Target price
$10.50
-34.8% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+34.8
Score
AI commentary
Post-earnings tone improved meaningfully after the beat-and-raise, and initial market coverage framed the print as better than expected. But this is a T+3 follow-up with still-thin analyst revision evidence, and some secondary coverage flagged Q2 guidance as soft versus consensus. With no usable social packet support and only medium coverage, the setup remains cautious rather than strongly bullish.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-05catalystQ1 beat and higher full-year EPS guide improved the near-term setupHigh impact
Integra reported Q1 2026 revenue of $391.9 million, adjusted EPS of $0.54, reaffirmed full-year revenue guidance, and raised full-year adjusted EPS guidance to $2.40-$2.50 from $2.30-$2.40, alongside better gross margin and EBITDA. That is the clearest post-earnings positive signal, though it is partly tempered by softer Q2 guidance. [#8-K-2026-05-05]
2026-06-30eventEnd-June SurgiMend production target is a concrete execution checkpointHigh impact
Management said Braintree remains on track to begin SurgiMend production by the end of June 2026 to support a fourth-quarter launch, while also citing stronger Integra Skin supply reliability and the return of PriMatrix and Durepair. Hitting that manufacturing milestone would strengthen confidence that the turnaround is becoming operationally durable. [#8-K-2026-05-05]
2026-12-31catalystRemediation and transformation execution could rebuild the multiple, but it is still a monitoring thesisHigh impact
The longer-term upside depends on sustained quality-system remediation, compliance-master-plan execution, supply normalization, and margin recovery rather than on a single demand surge. Q1 showed improvement, but the company still carries meaningful execution baggage from prior manufacturing and quality issues. [#10-K-2026-02-26]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology